Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1

British Journal of Dermatology

Volumn 136, Issue 4, 1997, Pages 542-547

  Mrowietz, U ^a   Jessat, H ^a   Schwarz, A ^b   Schwarz, T ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DITHRANOL; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; PSORIASIS;

EID: 0030975215     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb02138.x     Document Type: Article

References (40)

1. Galewsky D. Über Cignolin, ein Ersatzpräparat des Chrysarobins. Dermatol Wochenschr 1916; 62: 100-15.
2. Unna PG. Cignolin als Heilmittel der Psoriasis. Dermatol Wochenschr 1916; 62: 116-37.
3. Reichert U, Jaques Y, Grangeret M, Schmidt R. Anti-respiratory and anti-proliferative activity of anthralin in cultured human keralinocytes. J Invest Dermatol 1985; 84: 130-4.
4. Schröder JM, Kosfeld U, Christophers E. Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils. J Invest Dermatol 1985; 85: 30-4.
5. Schröder JM. Anthralin (1,8-dihydroxyanthrone) is a potent inhibitor of leukotriene production and LTB 4-omega oxidation by human neutrophils. J Invest Dermatol 1986; 87: 624-9.
6. Mrowietz U, Falsafi M, Schröder JM, Christophers E. Inhibition of human monocyte functions by anthralin. Br J Dermatol 1992; 127: 382-6.
7. Christophers E, Mrowietz U. The inflammatory infiltrate in psoriasis. Clinics Dermatol 1995; 13: 131-5.
8. Van den Oord JJ, de Wolf-Peeters C. Epithelium-lining macrophages in psoriasis. Br J Dermatol 1994; 130: 589-94.
9. Wortmann S, Boehncke W-H, Mielke V et al. Ultrastructure of macrophages lining the epidermo-dermal border in psoriatic skin ('lining cells'). Arch Dermatol Res 1993; 285: 85.
10. Tuschil A, Lam C, Haslberger A, Lindley I. Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol 1992; 99: 294-8.
11. Grossman RM, Krueger J, Yourish D et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86: 6367-71.
12. Zheng M, Yang H, Mrowietz U. Isolation of human monocyte subpopulations by single-step counterflow centrifugation elutriation using a Sanderson chamber. Phenotypical and functional characterization of isolated cells. Clin Biotechnol 1991; 3: 197-201.
13. Sticherling M, Schröder JM, Christophers E. Production and characterization of monoclonal antibodies against the novel neutrophil activating peptide NAP/IL-8. J Immunol 1989; 143: 1628-34.
14. Neuner P, Urbanski A, Trautinger F et al. Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol 1991; 97: 27-33.
15. Hopkins SJ, Humphreys M. Simple, sensitive and specific bioassay of interleukin-1. J Immunol Methods 1989; 120: 271-6.
16. Wiegrebe W, Müller K. Treatment of psoriasis with anthrones - chemical principles, biochemical aspects, and approaches to the design of novel derivatives. Skin Pharmacol 1995; 8: 1-24.
17. Kammerau B, Zesch A, Schaefer H. Absolute concentrations of dithranol and triacetyl-dithranol in the skin layers after local treatment: in vivo investigations with four different types of pharmaceutical vehicles. J Invest Dermatol 1975; 64: 145-9.
18. Schalla W, Bauer E, Schaefer H. Skin permeability of anthralin. Br J Dermatol 1981; 105 (Suppl. 20): 104-8.
19. Ohta Y, Katayama I, Funato T et al. In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions. Arch Dermatol Res 1991; 283: 351-6.
20. Schröder JM, Gregory H, Young J, Christophers E. Neutrophil-activating proteins in psoriasis. J Invest Dermatol 1992; 98: 241-7.
21. Takematsu H, Tagami H. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin. Arch Dermatol 1993; 129: 74-80.
22. Kulke R, Tödt-Pingel I, Rademacher D et al. Co-localized over-expression of GRO-α and IL-8 mRNA is restricted to the suprapapillary layers of psoriatic lesions. J Invest Dermatol 1996; 106: 526-30.
23. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.
24. Gearing AJH, Fincham NJ, Bird CR et al. Cytokines in skin lesions of psoriasis. Cytokine 1990; 2: 68-75.
25. Haskill S, Johnson C, Eierman D et al. Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. J Immunol 1988; 140: 1690-4.
26. Heinel LA, Singleton D, Miller M et al. Monocyte adherence to the subendothelial basement membrane increases interleukin-8 gene expression and antigen release. Inflammation 1995; 19: 517-27.
27. Mahnke K, Bhardwaj R, Sorg C. Heterodimers of the calcium-binding proteins MRP8 and MRP14 are expressed on the surface of human monocytes upon adherence to fibronectin and collagen. Relation to TNF-α, IL-6, and superoxide production. J Leukocyte Biol 1995; 57: 63-71.
28. Schopf RE, Straussfeld E. Stimulus-dependent increased generation of oxygen intermediates in monocytes and polymorphonuclear leukocytes in psoriasis. J Invest Dermatol 1985; 84: 73-6.
29. Koh MS, Majewski BB, Rhodes EL. Increased macrophage activity in psoriasis. Acta Derm Venereol (Stockh) 1985; 65: 194-8.
30. Ternowitz T. Monocyte and neutrophil chemotaxis in psoriasis. J Am Acad Dermatol 1986; 15: 1191-9.
31. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 1985; 277: 352-8.
32. Lee WY, Fischer SM, Butler AP, Locniskar MF. Modulation of interleukin-1 alpha mRNA expression in mouse epidermis by tumor promoters and antagonists. Mol Carcinog 1993; 7: 26-35.
33. Yamamoto S, Jiang H, Kato R. Inhibition of anthralin-caused skin tumor promotion and interleukin-1α production by potent immunosuppressant FK506. Cancer Lett 1994; 83: 185-9.
34. Katiyar SK, Rupp CO, Korman NJ et al. Inhibition of 12-O-tetradecanoylphorbol-13-acetate and other skin tumor-promoter-caused induction of epidermal interleukin-1 alpha mRNA and protein expression in SENCAR mice by green tea polyphenols. J Invest Dermatol 1995; 105: 394-8.
35. Schmidt KN, Podda M, Packer L, Baeuerle PA. Anti-psoriatic drug anthralin activates transcription factor NF-κB in murine keratinocytes. J Immunol 1996; 156: 4514-19.
36. Müller JM, Ziegler-Heitbrock HWL, Baeuerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiol 1993; 187: 233-56.
37. Hiscott J, Marois J, Garoufalis J et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 1993; 13: 6231-40.
38. Ku G, Flanagan MA. Similarities and differences between the interleukin-1 induction and action pathways in human macrophages. Int J Tissue React 1993; 15: 65-70.
39. Lee WY, Butler AP, Locniskar MF, Fischer SM. Signal transduction pathway(s) involved in phorbol ester and autocrine induction of interleukin-1 alpha mRNA in murine keratinocytes. J Biol Chem 1994; 269: 17971-80.
40. Cogswell JP, Godlevski MM, Wisely GB et al. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol 1994; 153: 712-23.